Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $7.4 million.

  • Cytosorbents' Receivables - Net rose 1197.74% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 1197.74%. This contributed to the annual value of $7.3 million for FY2024, which is 2085.05% up from last year.
  • Cytosorbents' Receivables - Net amounted to $7.4 million in Q3 2025, which was up 1197.74% from $7.7 million recorded in Q2 2025.
  • Cytosorbents' 5-year Receivables - Net high stood at $7.8 million for Q2 2024, and its period low was $4.5 million during Q4 2021.
  • Over the past 5 years, Cytosorbents' median Receivables - Net value was $6.1 million (recorded in 2023), while the average stood at $6.2 million.
  • Within the past 5 years, the most significant YoY rise in Cytosorbents' Receivables - Net was 4792.13% (2021), while the steepest drop was 1232.43% (2021).
  • Cytosorbents' Receivables - Net (Quarter) stood at $4.5 million in 2021, then rose by 25.24% to $5.7 million in 2022, then rose by 6.92% to $6.1 million in 2023, then rose by 20.85% to $7.3 million in 2024, then grew by 1.46% to $7.4 million in 2025.
  • Its Receivables - Net was $7.4 million in Q3 2025, compared to $7.7 million in Q2 2025 and $7.7 million in Q1 2025.